Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus antitoxin
- Development stage
- Approved
- Lead developer
- Trinomab Pharmaceutical
- Modality
- Antibody-Based Therapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Tetanus antitoxin is a medication derived from the serum of horses hyperimmunized against Clostridium tetani toxin. It provides temporary passive immunity by neutralizing circulating tetanus toxin, but does not affect toxin already bound to nerve tissues. It is used for prophylaxis and treatment of tetanus in individuals with high-risk wounds who are not fully immunized or whose immunization status is unknown. The equine-derived product carries a risk of hypersensitivity reactions and serum sickness, so human tetanus immunoglobulin (TIG) is preferred in humans when available[2][4][5]. In veterinary medicine, it remains widely used for animals at risk of or infected with tetanus[1][6].
- Brand names
- TETAVIN
- Other names
- 破伤风抗毒素Tetanus Antitoxin (Equine)Tetanus AntiserumATS
02
Targets
TTC (Tetanus neurotoxin heavy chain fragment C)
Beyond the preview
Go deeper on tetanus antitoxin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus antitoxin.